2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 278-282
Technology and Procedures, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult
PAPER

262 Preliminary analysis of a prospective, single-arm, single-center clinical study of aponermin combined with cybord in newly diagnosed systemic light chain amyloidosis

Kai Ding, MD, Lijuan Li, PhD2, Jia Song3, Fanglin Liu4, Rong Fu, MD5
1 Tianjin, Tianjin, Tianjin, China
2 Tianjin Medical University General Hospital, Tianjin, China
3 Tianjin Medical University General Hospital, Tianjin, China
4 Tianjin Medical University General Hospital, Tianjin, China
5 Tianjin, Tianjin, China

Background

For patients with newly diagnosed systemic light chain amyloidosis (AL), current first-line treatment options are limited. Aponermin (Apo), a novel circularly permuted TRAIL ligand, induces selective apoptosis in malignant plasma cells through death receptors DR4 and DR5. In this study (ChiCTR2500102256), we investigated the efficacy and safety of Apo combined with bortezomib, cyclophosphamide, and dexamethasone (CyBorD) regimen in newly diagnosed AL amyloidosis.

Methods

Eligible patients were aged 18–75 years with newly diagnosed AL amyloidosis and received Apo-CyBorD regimen (Apo: 10 mg/kg, iv, d1–5; Bor: 1.0 mg/m², ih, d1, 8, 15, 22; C: 300 mg/m², po, d1, 8, 15; D: 20 mg/d, po, d1, 2, 8, 9, 15, 16, 22, 23). The primary endpoint was overall response rate (ORR) after 8 cycles of treatment. Secondary endpoints included best hematologic response depth after 8 cycles, involved organ response rate, and safety.

Diagnosis, staging, and response evaluation criteria in this study were all based on the Guideline for the Diagnosis and Treatment of Systemic Light Chain Amyloidosis (2021 Revision).

Aponermin used in this study was provided by Wuhan Hiteck Biopharmaceutical Co., Ltd.

Results

As of July 21, 2026, eleven patients were evaluable for efficacy. Baseline median dFLC of 67.3 mg/L (43.8-666.7). Among these patients, 81.8%(9/11) of the patients had heart involvement, 72.7% (8/11) were classified as Mayo 2004 stage IIIa, 81.8% (9/11) were classified as Mayo 2012 stage III or above, 72.7%(8/11) had kidney involvement and 63.6% (7/11) classified as renal prognosis stage II or above. Regarding other baseline characteristics of the 11 patients, baseline median NT-proBNP was 3543 (range 41–8094) pg/mL, median cTnT was 0.048 (0.009–0.118) ng/mL, and 24-hour urine protein was 5.68 (0.078–11.04) g/24h. Baseline NT-proBNP > 1800 pg/mL was observed in 72.7% (8/11) of patients, and baseline 24-hour urine protein > 5.0 g/24h was observed in 54.5% (6/11) of patients.

With a median follow-up of 6.57 months (range 1.4–12.2 months) and a median of 4 treatment cycles (range 1–8 cycles), the hematologic ORR was 81.8% (9/11), with ≥ VGPR rate of 63.6% (7/11). Among the two patients who did not achieve PR, one had a decrease in dFLC, and the other had stable indicators. Cardiac response rate was 55.6% (5/9), with ≥ VGPR rate of 22.2% (2/9); renal response rate was 62.5% (5/8), with ≥ VGPR rate of 50% (4/8). In terms of time to response, median hematologic response time was 1.4 months (95% CI, 1.1–1.7), cardiac response time was 1.4 months (95% CI, 0.4–2.8), and renal response time was 2.3 months (95% CI, 0–4.7). To date, median PFS has not yet been reached, and none of the patients who achieved remission have experienced disease progression.

In terms of safety, treatment-related adverse events occurred in 72.7% (8/11) of patients, with no grade ≥ 3 adverse events. The most common events included hypokalemia (27.2%) and drug-induced liver injury (18.2%), all of which resolved with symptomatic supportive care.

Conclusion

The Apo + CyBorD regimen demonstrated deep hematologic and organ responses with favorable safety and tolerability in newly diagnosed AL amyloidosis in this preliminary analysis. These findings support further investigation of this therapeutic approach.

Kai Ding, MD: No relevant conflicts of interest to declare.